Document Detail

Reactivation of overt and occult hepatitis B infection in various immunosuppressive settings.
MedLine Citation:
PMID:  21915865     Owner:  NLM     Status:  In-Data-Review    
The aim of the study was to evaluate clinical and virological differences in HBV reactivation between patients with overt and occult HBV infection. Twenty-three consecutive patients with symptomatic HBV reactivation occurring during or after immunosuppressive therapy were enrolled in a retrospective study: 10 with reactivation of overt HBV infection (overt group) and 13 of occult HBV infection (occult group). Twenty-one patients were treated with nucleot(s)ide analogues after HBV reactivation. Regimens including rituximab or fludarabine were administered more frequently in the occult group (61% vs. 31%, respectively). HBV reactivation was severe frequently in the overt (40%) and occult groups (38.4%). Patients in the overt group showed higher HBV-DNA titers (1.1 × 10(8)  ± 1.4 × 10(8) vs. 5.1 × 10(5)  ± 6.8 × 10(5)  IU; P < 0.005). Seven patients died during HBV reactivation, two in the overt and five in the occult group. Of these seven patients, two remained untreated and five had been treated with Lamivudine; of the 16 patients showing remission of HBV reactivation, four had been treated with Lamivudine, four with Entecavir, two with Telbivudine, and six with Lamivudine plus Adefovir. It is concluded that HBV reactivation is life-threatening in patients with diseases inhibiting the immune response and/or receiving immunosuppressive drugs. Supportive therapy without antiviral drugs or Lamivudine monotherapy may not be effective for treating patients with HBV reactivation. J. Med. Virol. 83:1909-1916, 2011. © 2011 Wiley-Liss, Inc.
Nicola Coppola; Gilda Tonziello; Mariantonietta Pisaturo; Vincenzo Messina; Salvatore Guastafierro; Marco Fiore; Valentina Iodice; Caterina Sagnelli; Maria Stanzione; Nicolina Capoluongo; Giuseppe Pasquale; Evangelista Sagnelli
Related Documents :
24705595 - Repeat hiv testing at voluntary testing and counseling centers in croatia: successful h...
25060765 - Role of cyp27b1+2838 promoter polymorphism in the treatment of chronic hepatitis b hbea...
9330555 - Performance of a new, hiv/aids-targeted quality of life (hat-qol) instrument in asympto...
23599235 - Cohort profile: antiretroviral therapy cohort collaboration (art-cc).
25486595 - The export receptor crm1 forms a dimer to promote nuclear export of hiv rna.
21978675 - Discovery of highly potent small molecule hepatitis c virus entry inhibitors.
Publication Detail:
Type:  Journal Article     Date:  2011-08-23
Journal Detail:
Title:  Journal of medical virology     Volume:  83     ISSN:  1096-9071     ISO Abbreviation:  J. Med. Virol.     Publication Date:  2011 Nov 
Date Detail:
Created Date:  2011-09-14     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7705876     Medline TA:  J Med Virol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1909-16     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 Wiley-Liss, Inc.
Department of Public Medicine, Section of Infectious Diseases, Second University of Naples, Naples, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Lamivudine resistance mutations in European patients with hepatitis B and patients co-infected with ...
Next Document:  HBV DNA suppression in HBeAg-positive chronic hepatitis B patients treated with peginterferon or pla...